Compile Data Set for Download or QSAR
maximum 50k data
Found 241 with Last Name = 'reichelt' and Initial = 'c'
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108110(US8598206, Table 6, 19)
Affinity DataKi:  0.25nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108098(US8598206, Table 6, 7)
Affinity DataKi:  0.300nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108117(US8598206, Table 6, 2)
Affinity DataKi:  0.400nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108109(US8598206, 118 | US8598206, 122)
Affinity DataKi:  0.600nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108109(US8598206, 118 | US8598206, 122)
Affinity DataKi:  0.600nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108098(US8598206, Table 6, 7)
Affinity DataKi:  0.600nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108106(US8598206, Table 6, 15)
Affinity DataKi:  0.600nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108107(US8598206, Table 6, 16)
Affinity DataKi:  0.700nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108104(US8598206, Table 6, 13)
Affinity DataKi:  0.800nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108099(US8598206, Table 6, 8)
Affinity DataKi:  0.800nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108099(US8598206, Table 6, 8)
Affinity DataKi:  0.900nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108115(US8598206, Table 6, 24)
Affinity DataKi:  1nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 117 | US8598206, 123)
Affinity DataKi:  1nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108105(US8598206, Table 6, 14)
Affinity DataKi:  1nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 117 | US8598206, 123)
Affinity DataKi:  1nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  1.20nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  1.30nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108109(US8598206, 118 | US8598206, 122)
Affinity DataKi:  1.5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM47177(BDBM108100 | US8598206, Table 6, 9)
Affinity DataKi:  1.5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108109(US8598206, 118 | US8598206, 122)
Affinity DataKi:  1.5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM47178(BDBM108103 | US8598206, Table 6, 12)
Affinity DataKi:  1.5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108115(US8598206, Table 6, 24)
Affinity DataKi:  1.5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108110(US8598206, Table 6, 19)
Affinity DataKi:  1.5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108096(US8598206, Table 6, 5)
Affinity DataKi:  1.80nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108097(US8598206, Table 6, 6)
Affinity DataKi:  2nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108105(US8598206, Table 6, 14)
Affinity DataKi:  2nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108106(US8598206, Table 6, 15)
Affinity DataKi:  2nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108107(US8598206, Table 6, 16)
Affinity DataKi:  2nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM47177(BDBM108100 | US8598206, Table 6, 9)
Affinity DataKi:  2nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108111(US8598206, Table 6, 20)
Affinity DataKi:  2.20nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108117(US8598206, Table 6, 2)
Affinity DataKi:  2.70nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  2.70nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108101(US8598206, Table 6, 10)
Affinity DataKi:  3nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108095(US8598206, Table 6, 4)
Affinity DataKi:  3nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108095(US8598206, Table 6, 4)
Affinity DataKi:  3.80nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108104(US8598206, Table 6, 13)
Affinity DataKi:  4nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 117 | US8598206, 123)
Affinity DataKi:  4nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108108(US8598206, 117 | US8598206, 123)
Affinity DataKi:  4nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi:  5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108096(US8598206, Table 6, 5)
Affinity DataKi:  5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108118(US8598206, Table 6, 1)
Affinity DataKi:  5.30nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108097(US8598206, Table 6, 6)
Affinity DataKi:  7.5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108101(US8598206, Table 6, 10)
Affinity DataKi:  7.5nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108118(US8598206, Table 6, 1)
Affinity DataKi:  8nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM47178(BDBM108103 | US8598206, Table 6, 12)
Affinity DataKi:  9nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108116(US8598206, Table 6, 3)
Affinity DataKi:  9.40nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108111(US8598206, Table 6, 20)
Affinity DataKi:  20nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108112(US8598206, Table 6, 21)
Affinity DataKi:  20nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM47178(BDBM108103 | US8598206, Table 6, 12)
Affinity DataKi:  20nMAssay Description:Inhibition of human FXa was determined by the method described in [0092]-[0098] using activated human Factor X from Enzyme Research Laboratories at 5...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVitamin K-dependent protein C(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM47178(BDBM108103 | US8598206, Table 6, 12)
Affinity DataKi:  27nMAssay Description:Inhibition of human aPC was determined by the method described in [0092]-[0098] using human activated protein C from Enzyme Research Laboratories at ...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 241 total ) | Next | Last >>
Jump to: